Navigation Links
Stem cell study offers hope for Parkinson's patients
Date:8/23/2011

Scientists have for the first time generated stem cells from one of the most rapidly progressing forms of Parkinson's disease.

The development will help research into the condition as it will enable scientists to model the disease in the laboratory to shed light on why certain nerve cells die.

Scientists, funded with a 300,000 grant from the charity Parkinson's UK, took skin samples from a patient diagnosed with one of the most progressive types of Parkinson's.

The research, led by the University of Edinburgh in collaboration with UCL (University College London), then used these skin cells to generate brain nerve cells affected by the disease.

The ability to generate these nerve cells will make it easier to monitor the effectiveness of potential new drugs that could slow or halt progress of the condition.

The aim would be to find drugs that can prevent the death of these key cells known as neurons which break down as a result of Parkinson's.

Dr Tilo Kunath, of the University of Edinburgh's Medical Research Council Centre for Regenerative Medicine, said: "Current drugs for Parkinson's alleviate symptoms of the condition. Modelling the disease in a dish with real Parkinson's neurons enables us to test drugs that may halt or reverse the condition.

"This study provides an ideal platform to gain fresh insight into the condition, and opens a new area of research to discover disease-modifying drugs."

The neuron cells were generated from a patient with a form of Parkinson's that progresses rapidly and can be diagnosed in people in their early 30s.

People with this form of Parkinson's have twice as many of the genes that produce a protein alpha synuclein compared with the general population.

Although this form of Parkinson's is rare the protein involved is linked to virtually all types of the disease.

Dr Michael Devine, of the UCL Institute of Neurology said, "Understanding such a progressive form of the disease will give us insight into different types of Parkinson's. As this type of Parkinson's progresses rapidly it will also make it easier to pick up the effects of drugs tested to prevent nerve cells targeted by the disease from dying."

The research was published in the journal Nature Communications.

Dr Kieran Breen, Director of Research and Development at Parkinson's UK, said: "Although the genetic mutation that leads to this progressive form of Parkinson's is rare this exciting study has the potential to bring about a huge breakthrough in Parkinson's research.

"This is just the kind of innovative research that Parkinson's UK is committed to funding as we move closer to a cure."


'/>"/>

Contact: Tara Womersley
tara.womersley@ed.ac.uk
44-131-650-9836
University of Edinburgh
Source:Eurekalert

Related biology technology :

1. Randomized Study Comparing Cell Therapeutics OPAXIO (Paclitaxel Poliglumex) and Radiotherapy to Standard of Care Temozolomide and Radiotherapy Treatment Open for Enrollment
2. Effient® (Prasugrel) Showed Significant 26 Percent Reduction in Cardiovascular Events Over Clopidogrel in New Core Clinical Cohort Population Sub-Analysis of the TRITON-TIMI 38 Pivotal Study
3. Microbial study reveals sophisticated sensory response
4. BioMarin Provides Update on GALNS Phase 1/2 Extension Study (MOR-100)
5. New Study Reports CancerTYPE ID Expands Tumor Type Coverage and Demonstrates Clinical Utility
6. Keryx Biopharmaceuticals Announces Completion of Patient Enrollment in KRX-0401 (Perifosine) Phase 3 Refractory Advanced Colorectal Cancer Study
7. BioDelivery Sciences Announces Completion of BEMA Buprenorphine Phase 3 Chronic Pain Study
8. As New Data Wave Begins, a Gene Study in One Disease Discovers Mutations in an Unrelated Disease
9. Convergence Pharmaceuticals Announces Start of Phase II Study for its Selective Nav 1.7 blocker CNV1014802
10. Cadmium selenide quantum dots degrade in soil, releasing their toxic guts, study finds
11. Diesel fumes pose risk to heart as well as lungs, study shows
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/25/2016)... Phoenix, AZ (PRWEB) , ... May 25, 2016 ... ... Arizona, Dr. Michael Fitzmaurice recently became double board-certified in surgery and surgery of ... 31, 2015. Dr. Fitzmaurice is no stranger to going above and beyond in ...
(Date:5/25/2016)... ... May 25, 2016 , ... Scientists at the University of Athens say ... mesothelioma may be hampering the research that could lead to one good one. Surviving ... read it now. , The team evaluated 98 mesothelioma patients who ...
(Date:5/25/2016)... ... 2016 , ... Lady had been battling arthritis since the age of two ... knee. Lady’s owner Hannah sought the help of Dr Jeff Christiansen of Superior ... cruciate ligament and help with the pain of Lady’s arthritis. Dr Christiansen suggested that ...
(Date:5/24/2016)... , ... May 24, 2016 , ... ... diabetes, and traumatic injuries, will be accelerated by research at Worcester Polytechnic Institute ... engines of wound healing and tissue regeneration. , The novel method, developed by ...
Breaking Biology Technology:
(Date:3/31/2016)... , March 31, 2016  Genomics firm Nabsys has ... CEO, Barrett Bready , M.D., who returned to ... the original technical leadership team, including Chief Technology Officer, ... Product Development, Steve Nurnberg and Vice President of Software ... the company. Dr. Bready served as CEO ...
(Date:3/21/2016)... Unique technology combines v ... security   Xura, Inc. ... digital communications services, today announced it is working alongside ... customers, particularly those in the Financial Services Sector, the ... within a mobile app, alongside, and in combination with, ...
(Date:3/14/2016)... NXTD ) ("NXT-ID" or the "Company"), a company ... of a new series of commercials on Time Warner Cable ... .  The commercials will air on Bloomberg TV, Fox Business ... show. --> NXTD ) ("NXT-ID" or the "Company"), ... the airing of a new series of commercials on Time ...
Breaking Biology News(10 mins):